- Net loss widened to $18.7 million in Q3 compared to $12.8 million in the prior year period.
- Total operating expenses expanded to over $20 million driven by higher R&D investments.
- Cash and cash equivalents stood at $75.2 million as of September 30.
Why is $CTNM moving today? · SEC 8-K archive
$CTNM SEC Filing Alert & Real-Time AI Stock Impact Analysis
T0 SEO archive for $CTNM: filings appear instantly. AI score, direction and bullet analysis unlock publicly after 4 hours (VIP sees them live).
FAQ: $CTNM filing catalyst
Why did $CTNM trigger an AI stock catalyst alert?
$CTNM triggered a Stock Catalyst AI alert on 2026-11-03 00:00:00 UTC for a SEC 8-K filing (AI Score: -2.0/10). Headline: Contineum Therapeutics Reports Q3 Net Loss Widening to $18.7M. Key points: - Net loss widened to $18.7 million in Q3 compared to $12.8 million in the prior year period. - Total operating expenses expanded to over $20 million driven by higher R&D investments. - Cash and cash equivalents stood at $75.2 million as of September 30.
How did $CTNM stock react after the SEC filing?
After the SEC 8-K for $CTNM, observed market reaction: T0 price $9.69. Past moves do not guarantee future results.
Where can I get real-time $CTNM SEC filing alerts?
Stock Catalyst AI pushes real-time SEC 8-K alerts for $CTNM via Telegram and the VIP Web Terminal from €10/month.